1.
Emerging technologies for point-of-care CD4 T-lymphocyte counting
by Boyle, David S
Trends in biotechnology (Regular ed.), 2011, Vol.30 (1), p.45-54
2.
Use of antiretroviral therapy in resource-limited countries in 2006 : distribution and uptake of first-and second-line regimens
by RENAUD-THERY, Francoise
AIDS (London), 2007, Vol.21 (Suppl 4), p.S89-S95
3.
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, random...
by Cohen, Calvin J, Dr
The Lancet (British edition), 2011, Vol.378 (9787), p.229-237
4.
Field effectiveness of combination antiretroviral prophylaxis for the prevention of mother-to-child HIV transmission in rural Zambia
by GARTLAND, Matthew G
AIDS (London), 2013, Vol.27 (8), p.1253-1262
5.
Peer counselors' role in supporting patients' adherence to ART in Ethiopia and Uganda
by Gusdal, Annelie K.
AIDS care, 2011-06-01, Vol.23 (6), p.657-662
6.
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
by Molina, Jean-Michel, Dr, Prof
The Lancet (British edition), 2011, Vol.378 (9787), p.238-246
7.
Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study
by Grant, Robert M, Prof
The Lancet infectious diseases, 2014, Vol.14 (9), p.820-829
8.
Low Prevalence of Transmitted HIV Type 1 Drug Resistance Among Antiretroviral-Naive Adults in a Rural HIV Clinic in Kenya
by Hassan, Amin S
AIDS research and human retroviruses, 2013-01-01, Vol.29 (1), p.129-135
9.
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
by Margolis, David A
The Lancet (British edition), 2017-09-23, Vol.390 (10101), p.1499-1510
10.
Antiviral activity, safety, and pharmacokinetics/ pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
by MIN, Sherene
AIDS (London), 2011, Vol.25 (14), p.1737-1745
11.
The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?
by Vitoria, Marco
AIDS (London), 2018-07-31, Vol.32 (12), p.1551-1561
12.
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
by Fellay, Jacques
The Lancet (British edition), 2002-01-05, Vol.359 (9300), p.30-36
13.
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcr...
by Arribas, José R, Dr
The Lancet infectious diseases, 2015, Vol.15 (7), p.785-792
14.
Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention
by VAN DER STRATEN, Ariane
AIDS (London), 2012, Vol.26 (7), p.F13-F19
15.
Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT...
by Perez-Molina, José A, PhD
The Lancet infectious diseases, 2015, Vol.15 (7), p.775-784
16.
Work-related Barriers and Facilitators to Antiretroviral Therapy Adherence in Persons Living with HIV Infection
by Torres-Madriz, Gilberto
AIDS and behavior, 2010-01-21, Vol.15 (7), p.1475-1482
17.
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial
by McCormack, Sheena, Prof
The Lancet (British edition), 2016, Vol.387 (10013), p.53-60
18.
Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs
by Siliciano, Robert F
Nature medicine, 2008-07, Vol.14 (7), p.762-766
19.
Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 random...
by Raffi, François, Prof
The Lancet (British edition), 2014, Vol.384 (9958), p.1942-1951
20.
A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model
by Yant, Stephen R
Nature medicine, 2019-09, Vol.25 (9), p.1377-1384
